M
Monique Hanse
Researcher at Catharina Ziekenhuis
Publications - 15
Citations - 1021
Monique Hanse is an academic researcher from Catharina Ziekenhuis. The author has contributed to research in topics: Bevacizumab & Lomustine. The author has an hindex of 9, co-authored 13 publications receiving 820 citations.
Papers
More filters
Journal ArticleDOI
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Hendrikus J. Dubbink,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Winand N.M. Dinjens,Roelien H. Enting,Martin J B Taphoorn,Franchette W P J van den Berkmortel,Rob L. H. Jansen,Dieta Brandsma,Jacoline E C Bromberg,Irene van Heuvel,René M. Vernhout,Bronno van der Holt,Martin J. van den Bent +20 more
TL;DR: The first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma reported overall survival at 9 months, and the combined treatment was well tolerated.
Journal ArticleDOI
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy : A Report from the BELOB Trial
Lale Erdem-Eraslan,Martin J. van den Bent,Youri Hoogstrate,Hina Naz-Khan,Andrew P. Stubbs,Peter J. van der Spek,René Böttcher,Ya Gao,Maurice de Wit,Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Bronno van der Holt,René M. Vernhout,Peter A. E. Sillevis Smitt,Johan M. Kros,Pim J. French +20 more
TL;DR: It is demonstrated that tumors assigned to the IGS-18 or "classical" subtype and treated with beva+CCNU showed a significant benefit in progression-free survival and a trend toward benefit in overall survival, whereas other subtypes did not exhibit such benefit.
Journal ArticleDOI
A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.
Walter Taal,HM Oosterkamp,Annemiek M E Walenkamp,Laurens V. Beerepoot,Monique Hanse,Jan Buter,Aafke H. Honkoop,Dolf Boerman,Filip de Vos,Rob L. H. Jansen,Franchette W P J van den Berkmortel,Dieta Brandsma,Johan M. Kros,Jacoline E C Bromberg,Irene van Heuvel,Marion Smits,Bronno van der Holt,René M. Vernhout,Martin J. van den Bent +18 more
TL;DR: Patients with histologically proven glioblastoma, with a first recurrence after chemo-irradiation with temozolomide, having concluded radiotherapy more than 3 months ago, with adequate bone marrow, renal and hepatic function, and WHO performance status (PS) 0-2 are enrolled.
Journal ArticleDOI
Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study
Kaspar Draaisma,Kaspar Draaisma,Aikaterini Chatzipli,Martin J B Taphoorn,Melissa Kerkhof,Astrid Weyerbrock,Marc Sanson,Ann Hoeben,Slavka Lukacova,Giuseppe Lombardi,Sieger Leenstra,Monique Hanse,Ruth Fleischeuer,Colin Watts,Joseph H. McAbee,Nicos Angelopoulos,Thierry Gorlia,Vassilis Golfinopoulos,Johan M. Kros,Roel G.W. Verhaak,Vincent Bours,Martin J. van den Bent,Ultan McDermott,Pierre A. Robe,Pierre A. Robe,Pim J. French +25 more
TL;DR: This large cohort of matched primary and recurrent IDH WT tumors establishes the frequency of GBM driver instability after chemoradiotherapy with temozolomide, which allows per gene or pathway calculation of trial size at tumor recurrence, using molecular data of the primary tumor only.
Journal ArticleDOI
Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment.
TL;DR: The authors reviewed all CLL patients treated in a tertiary referral center to assess the incidence and outcome of leptomeningeal involvement (LI) in CLL and found an incidence of 1–2% of LI.